CN1981819B - Tree-peony root bark component, its preparation, making method and use - Google Patents
Tree-peony root bark component, its preparation, making method and use Download PDFInfo
- Publication number
- CN1981819B CN1981819B CN2005101223493A CN200510122349A CN1981819B CN 1981819 B CN1981819 B CN 1981819B CN 2005101223493 A CN2005101223493 A CN 2005101223493A CN 200510122349 A CN200510122349 A CN 200510122349A CN 1981819 B CN1981819 B CN 1981819B
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- solution
- preparation
- sample
- cortex moutan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 5
- 238000002360 preparation method Methods 0.000 title claims description 31
- 240000005001 Paeonia suffruticosa Species 0.000 title abstract description 4
- 235000003889 Paeonia suffruticosa Nutrition 0.000 title abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000284 extract Substances 0.000 claims abstract description 18
- 238000001035 drying Methods 0.000 claims abstract description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 51
- 239000000243 solution Substances 0.000 claims description 38
- 239000003480 eluent Substances 0.000 claims description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000741 silica gel Substances 0.000 claims description 15
- 229910002027 silica gel Inorganic materials 0.000 claims description 15
- 229960001866 silicon dioxide Drugs 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- 239000012141 concentrate Substances 0.000 claims description 12
- 238000004262 preparative liquid chromatography Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 238000002953 preparative HPLC Methods 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 239000003208 petroleum Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 abstract description 22
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 abstract description 17
- 239000007788 liquid Substances 0.000 abstract description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 14
- 229940074391 gallic acid Drugs 0.000 abstract description 11
- 235000004515 gallic acid Nutrition 0.000 abstract description 11
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000005406 washing Methods 0.000 abstract description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 abstract 2
- 229910052710 silicon Inorganic materials 0.000 abstract 2
- 239000010703 silicon Substances 0.000 abstract 2
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 239000007791 liquid phase Substances 0.000 abstract 1
- 239000012071 phase Substances 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 239000000470 constituent Substances 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 101710088194 Dehydrogenase Proteins 0.000 description 10
- -1 tetradecane hydrocarbon Chemical class 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 8
- 239000012531 culture fluid Substances 0.000 description 8
- 239000012362 glacial acetic acid Substances 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 239000002547 new drug Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000005779 cell damage Effects 0.000 description 5
- 208000037887 cell injury Diseases 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 3
- BGHCVCJVXZWKCC-UHFFFAOYSA-N Tetradecane Natural products CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000003954 umbilical cord Anatomy 0.000 description 3
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical class NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 2
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 235000003935 Hippophae Nutrition 0.000 description 2
- 241000229143 Hippophae Species 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 2
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 2
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 2
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- BANPEMKDTXIFRE-PQTROMPISA-N (+)-Paeoniflorigenone Natural products O=C(OC[C@@H]1[C@@H]2O[C@]3(O)[C@@](C)(O2)CC(=O)[C@@H]1C3)c1ccccc1 BANPEMKDTXIFRE-PQTROMPISA-N 0.000 description 1
- AMQCWFKKFGSNNA-UHFFFAOYSA-N 2-butylcyclohexa-2,5-diene-1,4-dione Chemical group CCCCC1=CC(=O)C=CC1=O AMQCWFKKFGSNNA-UHFFFAOYSA-N 0.000 description 1
- KCAAGBCFVTYDEV-VFZPANTDSA-N 3-O-Methylpaeonisuffral Natural products O(C)[C@@]12OC[C@H]3[C@@H]4O[C@@](O)([C@@](C)(O4)C1)C[C@@H]23 KCAAGBCFVTYDEV-VFZPANTDSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- KLFIUQCKSSAFFU-QHOIGUMUSA-N Galloylpaeoniflorin Natural products O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@]23[C@]4(COC(=O)c5ccccc5)[C@@H]5O[C@@]2(C)C[C@@](O)(O5)[C@@H]4C3)O1)c1cc(O)c(O)c(O)c1 KLFIUQCKSSAFFU-QHOIGUMUSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- SXYRXUOTYBVVCK-UHFFFAOYSA-N OC=1C=C2C=CC(OC2=CC1)=O.OC=1C=C2C=CC(OC2=CC1)=O Chemical compound OC=1C=C2C=CC(OC2=CC1)=O.OC=1C=C2C=CC(OC2=CC1)=O SXYRXUOTYBVVCK-UHFFFAOYSA-N 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- FKUBIEWSGBVADJ-UHFFFAOYSA-N UNPD9765 Natural products C12CC=C3C4CC(=C)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C FKUBIEWSGBVADJ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000009465 diaoxinxuekang Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- FTNAQSRZVJECBA-UHFFFAOYSA-N diethyl benzene-1,2-dicarboxylate;3,4-diethylphthalic acid Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC.CCC1=CC=C(C(O)=O)C(C(O)=O)=C1CC FTNAQSRZVJECBA-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- KLFIUQCKSSAFFU-ANNBSXMPSA-N galloylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=C(O)C(O)=C(O)C=2)O1)O)C)OC(=O)C1=CC=CC=C1 KLFIUQCKSSAFFU-ANNBSXMPSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- BANPEMKDTXIFRE-LQPBRMSDSA-N paeoniflorigenone Chemical compound C([C@H]1[C@@H]2O[C@]3(O)C[C@H]1C(=O)C[C@@]3(O2)C)OC(=O)C1=CC=CC=C1 BANPEMKDTXIFRE-LQPBRMSDSA-N 0.000 description 1
- CLFSAVBFICIRCY-UHFFFAOYSA-N paeoniflorigenone Natural products CC12CC(=O)C3CC1(O)OC(O2)C3OC(=O)c4ccccc4 CLFSAVBFICIRCY-UHFFFAOYSA-N 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
An active component of tree peony bark is proportionally composed of paeoniflorin and gallic acid. Its preparing process includes such steps as breaking red sage root, adding ethyl acetate and alcohol, thermal extracting, concentrating to obtain extract, mixing it with silicon gel, separating with positive-phase silicon gel column, washing with petroether and ethyl acetate, eluting with chloroform and methanol, concentrating the eluting liquid, drying, and separating by liquid-phase chromatography. Its application is also disclosed.
Description
Technical field
The present invention relates to a kind of Chinese medicine extract for the treatment of cardiovascular disease, relate in particular to the active component that from Cortex Moutan, extracts, preparation and preparation method thereof and purposes, this active component mainly contains peoniflorin, two kinds of chemical compounds of gallic acid.
Background technology
Coronary heart disease and angina pectoris are harm humans health " first killers ", in recent years, along with the variation of China's population senescence and people's work, life, dietary structure and environment etc., the incidence rate of cardiovascular and cerebrovascular diseases such as coronary heart disease also increases year by year, and the people's physical and mental health in serious threat.In the natural product many active substances have resist myocardial ischemia, anoxia functions, some of them have been developed to treatment coronary heart disease and anginal new drug, as treat the medicine DIAOXINXUE KANG of coronary heart disease, it is by 8 kinds of pure Chinese medicinal preparations that steroid saponin is made that extract from Chinese medicine; Flavonihippophae is to be that raw material extracts the pure natural medical that processes with the Fructus Hippophae, and its effective ingredient is a Fructus Hippophae total flavones.Thereby from natural product, seek have resist myocardial ischemia, the active substance of anoxia physiologically active, be find, one of effective way of developing new drug.China's medicinal organism resource is very abundant, and its biological active substances is research and finds new drug guide chemicals, the natural treasure-house of developing new drug.At present, China extracts active substance from natural product, be used to be developed to treatment coronary heart disease, safety is good, toxicity is low new drug also seldom, from natural product, extract active substance, be developed to have and resist myocardial ischemia, be used for the treatment of coronary heart disease and anginal new drug, have significant application value and wide development prospect.
Cortex Moutan has another name called Cortex Moutan, is the root bark of dicotyledon medicine ranunculaceae peony (Paeonia suffruticosa Andr.).Ground such as distribution Hebei, Henan, Shandong, Sichuan, Shaanxi, Gansu.All there is cultivation all parts of the country, ground such as medical material main product Anhui, Sichuan, Gansu, Shaanxi, Hubei, Hunan, Shandong, Guizhou, and in addition, also produce in Yunnan, Zhejiang.Its cold nature, the acrid in the mouth hardship, the heart, liver, kidney channel are gone in cold, have heat clearing away, removing heat from blood, and blood, the effect of repercussive.Cortex Moutan is concocted and to be seen China's beam Dai Taohong scape the earliest and write in " variorums ", thinks: " all urge to break, remove the heart." in the medical book such as Compendium of Material Medica record " the Cortex Moutan core is not used as medicine, and need go it." studies show that: Cortex Moutan contains paeonol (Paeono1), paeoniflorin (Paeoniforin), hydroxypaeoniflorin, benzoylpaeoniflorin (Benzoylpaeoniflorin), benzoyl hydroxypaeoniflorin, Radix Paeoniae aglycon (Paeoniflorigenone), 6-Hydroxycoumarin (6-hydroxycoumarin) and gallic acid (GallicAcid), and benzoic acid, plant sterol, sucrose, glucose, arabinose etc.Contain benzoic acid (Benzoic Acid), tetradecane hydrocarbon (Tetradecane), 2-hydroxyl-4-methoxyl group-1-Phenylethanone. (2-hydroxy-4-methoxy acetophenone), 2 in the volatile oil, the two tertiary butyl 1,4-benzoquinone (2 of 6-, 6-ditert-butyl-p-Benzoquinone), diethyl phthalate (Diethyl Phthalate), isopropyl myristate chemical compound (Chen Yuejiao etc. such as (Isopropyl Myristate), Guangzhou food industry science and technology, 2002,18 (4): 36-37).People such as Wu Shaohua separate from Cortex Moutan first and have obtained following five kinds of chemical compounds: betulic acid (Betulinic Acid), betulin (Betulin), oleanolic acid (OleanolicAcid), 3 β, 23-dihydroxy-30-norolean-12,20 (29)-dien-28-oic acid, 3-O-methylpaeonisuffral (Wu Shaohua etc., Chinese herbal medicine, 2002,33 (8): 679-680).
Cortex Moutan has the degree of injury of alleviating effect to expeirmental myocardial ischemia, and can reduce myocardial oxygen consumption, increases coronary flow; think that Cortex Moutan has that to regulate blood capable, the effect of mediation blood vessels, thereby myocardial ischemia had protective effect (Ma Yuling etc.; the Shanxi medical magazine, 1984,13 (4): 212-214).Peoniflorin has antiplatelet aggregative activity, and antithrombotic effect is to the protective effect and the antitumor action of liver.Peoniflorin has blocking effect (Zhang Guangxin etc., Chinese Pharmacological circular, 2003,19 (8): 863-866) to myocardial cell Ica, L.Peoniflorin can increase neurocyte survival quantity, reduces mortality rate, excitatory neuron damage (Wu Yumei etc., Chinese J Pharmacol Toxicol, 2002,16 (3): 172-175) due to the antagonism KA.Peoniflorin has significant protective effect (Yang Jun etc., Chinese Journal of New Drugs, 2001,10 (6): 426-428) to PC12 cell injury due to the calcium overload.The colony that peoniflorin strengthens syndrome of deficiency of blood mouse bone marrow cells hematopoietic stem/progenitor cells forms ability; Peoniflorin can promote marrow stromal cell secretion Hemopoietic factor (G-CSF, GM-CSF, PDGF-α) etc., suppresses secretion (Gao Yue, Tianjin Chinese medicine, 2003,20 (6): 47-51) of hemopoietic inhibitive factor (M-CIP).
Summary of the invention
The object of the present invention is to provide a kind of moutan bark effective constituent.
Another object of the present invention is to provide the preparation method and its usage of this moutan bark effective constituent.
The present invention also provides the preparation that comprises moutan bark effective constituent.
The present invention is implemented with following technical scheme:
In the moutan bark effective constituent of the present invention, mainly contain peoniflorin and gallic acid.Wherein, by weight percentage, content of paeoniflorin is 70～80%, and the content of gallic acid is 10～20%.
Preferably, in the moutan bark effective constituent of the present invention, by weight percentage, content of paeoniflorin is 72～78%, and the content of gallic acid is 12～18%.
Best, in the moutan bark effective constituent of the present invention, by weight percentage, content of paeoniflorin is 74～76%, the content of gallic acid is 14～16%.
The preparation method of moutan bark effective constituent of the present invention, comprise the following steps: and will add ethyl acetate and ethanol after the Cortex Moutan pulverizing medicinal materials, heating extraction gets extracting solution, and extracting solution is condensed into extractum, and itself and silica gel mixed sample, with normal phase silicagel column it is separated, at first use petroleum ether and ethyl acetate, get eluent I as mobile phase, abandon it, change chloroform and methanol then as mobile phase, get eluent II, will get sample behind the eluent II concentrate drying; Continue to separate the sample that obtains with preparative liquid chromatography; The separation condition of preparative hplc: chromatographic column is a semi-preparative column, and mobile phase is water and acetonitrile, gradient elution.
Preferably, moutan bark effective constituent preparation method of the present invention, comprise the following steps: and to add ethyl acetate and ethanol (1: 0.8～1.2) after the Cortex Moutan pulverizing medicinal materials, reflux 0.8～1.2 hour, extract 1～3 time, merging filtrate gets extracting solution, extracting solution is condensed into extractum, and itself and silica gel are mixed sample, it is separated with normal phase silicagel column, at first use petroleum ether and ethyl acetate (47～53: 1) as mobile phase, get eluent I, abandon it, change chloroform and methanol (8～13: then 1) as mobile phase, get eluent II, will get sample behind the eluent II concentrate drying; Continue to separate the sample that obtains with preparative liquid chromatography; The separation condition of preparative hplc: chromatographic column is a semi-preparative column, and mobile phase is water and acetonitrile, and gradient elution, flow velocity are 2.8～3.2ml/min, and column temperature is a room temperature.
Best, moutan bark effective constituent preparation method of the present invention comprises the following steps: and will add ethyl acetate and ethanol (1: 1) after the Cortex Moutan pulverizing medicinal materials that reflux 1 hour is extracted 2 times, merging filtrate gets extracting solution; Extracting solution is condensed into extractum, and itself and silica gel mixed sample, with normal phase silicagel column it is separated, at first use petroleum ether and ethyl acetate (50: 1) as mobile phase, get eluent I, abandon it, change chloroform and methanol (10: 1) then as mobile phase, get eluent II, will get sample behind the eluent II concentrate drying; Continue to separate the sample that obtains with preparative liquid chromatography; The separation condition of preparative hplc: chromatographic column is semi-preparative column (Lichrospher C18; 10.0mm * 250mm, 5 μ m), mobile phase is water (A) and acetonitrile (B), and the gradient elution program is as follows: in the time of 0 minute, mobile phase A is that 80% aqueous solution, Mobile phase B are 20% acetonitrile solution; In the time of 40 minutes, mobile phase A is that 20% aqueous solution, Mobile phase B are 80% acetonitrile solution; In the time of 50 minutes, mobile phase A is that 5% aqueous solution, Mobile phase B are 95% acetonitrile solution; Flow velocity is 3ml/min, and column temperature is a room temperature; Sample 100% dissolve with ethanol separates through preparative liquid chromatography, collects solution at time period 7.6～9.7min, and solution obtains active component behind concentrate drying.
Moutan bark effective constituent of the present invention can be used as active component, adds the adjuvant of accepting on the pharmaceutics, makes preparation according to the preparation method of the preparation of putting down in writing on the pharmaceutics.
Moutan bark effective constituent of the present invention can also add the adjuvant of accepting on the pharmaceutics as one of active component, makes preparation according to the preparation method of the preparation of putting down in writing on the pharmaceutics.
Described preparation comprises injection, drip liquid, injectable powder, granule, tablet, electuary, powder, oral liquid, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, sucks agent, granule, pill, unguentum, sublimed preparation, spray, drop pill, disintegrating agent, oral cavity disintegration tablet, micropill etc.
Moutan bark effective constituent of the present invention and preparation thereof can be used in preparation treatment, angiocardiopathy preventing medicine.
Beneficial effect of the present invention is:
1. use normal phase silicagel column in the extraction and separation process of the present invention, can remove impurity such as desaccharide, protein, aminoacid effectively, improved content of effective, adopted preparative hplc simultaneously, can obtain effective ingredient fast and accurately.
2. moutan bark effective constituent chemical constituent provided by the invention is simply clear and definite, is easier to illustrate its mechanism of action on pharmacological research, is easier to the quality control of medicine aborning.
Description of drawings
Fig. 1 is the HPLC analysis chart of moutan bark effective constituent of the present invention.
The specific embodiment
Further describe flesh and blood of the present invention and beneficial effect below in conjunction with embodiment, this embodiment only is used to the present invention is described but not limitation of the present invention.
The preparation of embodiment one moutan bark effective constituent
Ethyl acetate and ethanol will be added after the 200g Cortex Moutan pulverizing medicinal materials, heating extraction gets extracting solution, extracting solution is condensed into extractum 16.8g, and itself and silica gel are mixed sample, it is separated with normal phase silicagel column, at first use petroleum ether and ethyl acetate as mobile phase, get eluent I, abandon it, change chloroform and methanol then as mobile phase, get eluent II, will get sample 3.9g behind the eluent II concentrate drying; Continue to separate the sample that obtains with preparative liquid chromatography; The separation condition of preparative hplc: chromatographic column is a semi-preparative column, and mobile phase is water and acetonitrile, gradient elution.Sample 100% dissolve with ethanol separates through preparative liquid chromatography, collects solution at time period 7.6～9.7min, obtains active component 0.34g behind the concentrate drying.
The preparation of embodiment two moutan bark effective constituents
Ethyl acetate and ethanol (1: 0.8～1.2) will be added after the 500g Cortex Moutan pulverizing medicinal materials, reflux 0.8～1.2 hour, extract 1～3 time, merging filtrate gets extracting solution, extracting solution is condensed into extractum 42g, and itself and silica gel mixed sample, with normal phase silicagel column it is separated, at first use petroleum ether and ethyl acetate (47～53: 1) as mobile phase, get eluent I, abandon it, change chloroform and methanol (8～13: then 1) as mobile phase, get eluent II, will get sample 11.8g behind the eluent II concentrate drying; Continue to separate the sample that obtains with preparative liquid chromatography; The separation condition of preparative hplc: chromatographic column is a semi-preparative column, and mobile phase is water and acetonitrile, and gradient elution, flow velocity are 2.8～3.2ml/min, and column temperature is a room temperature.Sample 100% dissolve with ethanol separates through preparative liquid chromatography, collects solution at time period 7.6～9.7min, obtains active component 0.91g behind the concentrate drying.
The preparation of embodiment three moutan bark effective constituents
Get Cortex Moutan medical material 250g, it is pulverized the back add ethyl acetate and ethanol (1: 1), reflux 1 hour is extracted 2 times, filtrate merge extracting solution.Extracting solution is condensed into extractum gets 22g, with extractum and silica gel mixed sample, separate with normal phase silicagel column, at first use petroleum ether and ethyl acetate (50: 1) as mobile phase, get eluent I, change chloroform and methanol (10: 1) then as mobile phase, get eluent II, get the 6.2g sample behind the concentrate drying.Continue to separate the sample that obtains with preparative liquid chromatography.The separation condition of preparative hplc: chromatographic column is semi-preparative column (the Lichrospher C18 of Chinese nation; 10.0mm * 250mm, 5 μ m), mobile phase is water (A) and acetonitrile (B), and gradient sees Table 2, and flow velocity is 3ml/min, and column temperature is a room temperature.Sample 100% dissolve with ethanol separates through preparative liquid chromatography, collects solution at time period 7.6～9.7min, obtains active component 0.49g behind the concentrate drying.
The analysis of embodiment four moutan bark effective constituents
(1) assay of peoniflorin, gallic acid (high performance liquid chromatography) in the Cortex Moutan extract
Chromatographic conditionChromatographic column Agilent Zorbax SB-C18 post (4.6mm * 150mm, 5 μ m); Adopt gradient elution, mobile phase A is 0.2% glacial acetic acid aqueous solution mutually, and Mobile phase B is mutually for containing the acetonitrile solution of 0.2% glacial acetic acid; The gradient elution program is as follows: in the time of 0 minute, mobile phase A is that 90% 0.2% glacial acetic acid aqueous solution, Mobile phase B are the acetonitrile solution of 10% 0.2% glacial acetic acid; In the time of 10 minutes, mobile phase A is that 50% 0.2% glacial acetic acid aqueous solution, Mobile phase B are the acetonitrile solution of 50% 0.2% glacial acetic acid; In the time of 30 minutes, mobile phase A is that 5% 0.2% glacial acetic acid aqueous solution, Mobile phase B are the acetonitrile solution of 95% 0.2% glacial acetic acid; Flow velocity 0.5mLmin
-1It is long to detect the wavelength all-wave; 30 ℃ of column temperatures; ELSD condition: 100 ℃ of drift tube temperatures; Nitrogen flow rate 1.4L/min
The preparation of need testing solutionTake by weighing this product, in volumetric flask, be diluted to scale, shake up, promptly with dissolve with methanol solution.
Assay methodThe accurate need testing solution of drawing injects chromatograph of liquid, measures, promptly.
(2) above-mentioned Cortex Moutan extract HPLC-ELSD finger printing
Assay methodMeasure (high performance liquid chromatography) referring to the peoniflorin in (1) above-mentioned Cortex Moutan extract, gallic acid content.The record chromatograph time is 30 minutes.
Analysis resultThe HPLC-ELSD analysis of spectra of moutan bark effective constituent is seen Fig. 1, and 1 among Fig. 1,2 is respectively peoniflorin, gallic acid.
Among the present invention, the structural formula of peoniflorin is:
Among the present invention, the structural formula of galloylpaeoniflorin is:
The preparation of embodiment five drop pill
Get moutan bark effective constituent 0.5g and 10.5g Polyethylene Glycol-6000 mix homogeneously of embodiment three, heating and melting moves in the drop pill drip irrigation behind the change material, and in ℃ liquid paraffin of medicine liquid droplet to 6～8, oil removing makes 400 of drop pill.
The preparation of embodiment six lyophilized injectable powders
Get moutan bark effective constituent 0.5g, glucose 4.5g, sodium thiosulfate 0.9g and the distilled water 1ml of embodiment three, behind the said components mix homogeneously, lyophilization, 500 of packing, promptly.
The preparation of embodiment seven lyophilized injectable powders
Get Lignum Dalbergiae Odoriferae oil 1.5g, join in the saturated hydroxypropyl of 13ml, stirring and dissolving filters, and the filtrate cold drying gets the clathrate powder of Lignum Dalbergiae Odoriferae oil and hydroxypropyl.Except that above-mentioned Lignum Dalbergiae Odoriferae oil closes the clathrate powder of hydroxypropyl, get Cortex Moutan extract 0.5g, mannitol 5.5g, calcium disodium edetate 0.9g and the distilled water 2ml of embodiment three again, behind the said components mixing, lyophilization, 300 of packing, promptly.
The pharmacological evaluation of embodiment eight moutan bark effective constituents
1 pharmacological model: neonatal rat myocardial cell hypoxic-ischemic model
Former generation myocardial cell cultivation After 1～3 day SD neonatal rat that is born was put to death, it was dirty to core, and subtracts into 1mm after PBS liquid cleans
3About fragment.With 0.125% trypsin Sigma, USA)+0.05% (Gibco is USA) in 37 degree digestion 3～4 times for collagenase II.The differential adherent method was separated into fibrocyte after 1.5 hours, and cell suspension is transferred to (every hole about 4 * 10 in 48 orifice plates
5Cell).(Gibco, (Falcon, USA) cell of cultivating 3-6 days supplies medicine efficacy screening USA) to add 10% hyclone through DMEM.Screen and replaced with serum-free medium in preceding 1 day.Cultivate 3～6 days myocardial cell, PBS washing back adds the pastille culture fluid.Place 95%N
2And 5%CO
2Anoxia is 6 hours in the incubator.Then at CO
2Reoxygenation is 3 hours in the incubator.Get cell conditioned medium liquid and measure LDH content.
Dosage regimenThe moutan bark effective constituent that extraction obtains is made into 10 with sugar-free Hanks liquid
-4G/mL test liquid, liposoluble constituent can add a small amount of DMSO hydrotropy (the DMSO final concentration is controlled at below 0.2%).The final concentration of each component in culture fluid is controlled at 10
-5G/mL.
The lactic acid dehydrogenase assayLactic acid dehydrogenase content can be represented the cell injury degree in the cell culture fluid.The lactic acid dehydrogenase content that bleeds in the supernatant is high more, shows that cell injury is also remarkable.The determination of lactate dehydrogenase test kit builds up bio-engineering research institute available from Nanjing.Assay method is: get 30 microlitre cell conditioned medium liquid, add 50 microlitre substrate buffer and 10 microlitre lactic dehydrogenase enzyme cofactors, 37 degree vibrations 15 minutes add 50 microlitre 2,4 dinitrophenyl hydrazines again, 37 degree vibrations 15 minutes.Parallel blank.Extract reaction solution 50 microlitres and add 200 microlitre 0.4mol/L sodium hydroxide solutions, leave standstill 3～4 minutes after, measure shading value with microplate reader in 450nm.
Drug effect result
All data are represented with the mean value variance.Adopt monolateral variance analysis and T check carrying out statistical analysis.Compare with model group, P＜0.05 is thought significantly effectively.Drug effect the results are shown in Table 1.According to myocardial cell lactic acid dehydrogenase (LDH) testing result, moutan bark effective constituent has the highly significant effect to reducing LDH release.
Table 1
2 pharmacological models: huve cell anoxia reoxygenation model
Former generation huve cell cultivationGet the healthy newborn umbilical cord, clean the interior residual bloodstain of vein blood vessel with 30～50mlHanks liquid.Look the 0.1% collagenase I that umbilical cord length adds respective amount, change incubator digestion 15～20 minutes over to.Subsequently Digestive system in the umbilical cord is carefully collected in the beaker, and with Hanks liquid with beaker rinse twice, collect in the lump and be sub-packed in centrifuge tube in the beaker, centrifugal 10 minutes of 900rpm.Supernatant is removed in suction, with the abundant dissolution precipitation of M199 culture fluid (contain 10% hyclone, 100U/ml is two anti-, 0.15mg/ml Heparin, 10uM VC).Gained cell suspension is sub-packed in 5cm
2Culture bottle places in the incubator and cultivates.Changed in second day and adopt the M199 culture fluid that contains 30ug/ml ECGS, changed a culture fluid and be paved with the bottom surface in per afterwards three days until cell.Used cell is former generation endotheliocyte.The culture bottle inner cell is seeded to 96 orifice plates before the modeling and cultivated one day, used cell concentration is 3.5～40,000/hole.During modeling, inhale and abandon old M199 culture fluid, adding pastille does not have phenol red M199 culture fluid, and every hole total amount is 100ul.Place 95%N
2And 5%CO
2Anoxia is 12 hours in the incubator, then at CO
2Reoxygenation is 2 hours in the incubator.Get cell conditioned medium liquid and measure LDH content and NO content.
Dosage regimenThe moutan bark effective constituent that extraction obtains is made into 10 with sugar-free Hanks liquid
-4G/mL test liquid, liposoluble constituent can add a small amount of DMSO hydrotropy (the DMSO final concentration is controlled at below 0.2%).The final concentration of each component in no phenol red M199 culture fluid is controlled at 10
-5G/mL.
The lactic acid dehydrogenase assayLactic acid dehydrogenase content can be represented the cell injury degree in the cell culture fluid.The lactic acid dehydrogenase content that bleeds in the supernatant is high more, shows that cell injury is also remarkable.The determination of lactate dehydrogenase test kit builds up bio-engineering research institute available from Nanjing.Assay method is: get 30 microlitre cell conditioned medium liquid, add 50 microlitre substrate buffer and 10 microlitre lactic dehydrogenase enzyme cofactors, 37 degree vibrations 15 minutes add 50 microlitre 2,4 dinitrophenyl hydrazines again, 37 degree vibrations 15 minutes.Parallel blank.Extract reaction solution 50 microlitres and add 200 microlitre 0.4mol/L sodium hydroxide solutions, leave standstill 3～4 minutes after, measure shading value with microplate reader in 450nm.
Drug effect resultAll data are represented with the mean value variance.Adopt monolateral variance analysis and T check carrying out statistical analysis.Compare with model group, P＜0.05 is thought significantly effectively.Drug effect the results are shown in Table 2.According to endotheliocyte lactic acid dehydrogenase testing result, moutan bark effective constituent has the highly significant effect to reducing LDH release.
Table 2
Claims (3)
1. a Cortex Moutan extract is characterized in that, adopts following method preparation:
To add 1: 1 ethyl acetate and ethanol after the Cortex Moutan pulverizing medicinal materials, reflux 1 hour is extracted 2 times, and merging filtrate gets extracting solution; Extracting solution is condensed into extractum, and itself and silica gel mixed sample, with normal phase silicagel column it is separated, at first use 50: 1 petroleum ether and ethyl acetate as mobile phase, eluent I, abandon it, change 10: 1 chloroforms and methanol then as mobile phase, get eluent II, will get sample behind the eluent II concentrate drying; Continue to separate the sample that obtains with preparative liquid chromatography; The separation condition of preparative hplc: chromatographic column is semi-preparative column Lichrospher C18; 10.0mm * 250mm, 5 μ m, mobile phase A is that water and B are acetonitrile, the gradient elution program is as follows: in the time of 0 minute, mobile phase A is that 80% aqueous solution, Mobile phase B are 20% acetonitrile solution; In the time of 40 minutes, mobile phase A is that 20% aqueous solution, Mobile phase B are 80% acetonitrile solution; In the time of 50 minutes, mobile phase A is that 5% aqueous solution, Mobile phase B are 95% acetonitrile solution; Flow velocity is 3ml/min, and column temperature is a room temperature; Sample 100% dissolve with ethanol separates through preparative liquid chromatography, collects solution at time period 7.6～9.7min, and solution obtains active component behind concentrate drying.
2. contain the pharmaceutical formulation of the described Cortex Moutan extract of claim 1, it is characterized in that, make arbitrary pharmaceutical formulation that pharmaceutics is accepted according to the preparation method that pharmaceutics allows.
3. the application of the described Cortex Moutan extract of claim 1 in preparation treatment and angiocardiopathy preventing medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005101223493A CN1981819B (en) | 2005-12-14 | 2005-12-14 | Tree-peony root bark component, its preparation, making method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005101223493A CN1981819B (en) | 2005-12-14 | 2005-12-14 | Tree-peony root bark component, its preparation, making method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1981819A CN1981819A (en) | 2007-06-20 |
| CN1981819B true CN1981819B (en) | 2011-07-20 |
Family
ID=38164849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005101223493A Expired - Fee Related CN1981819B (en) | 2005-12-14 | 2005-12-14 | Tree-peony root bark component, its preparation, making method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1981819B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101574410B (en) * | 2008-05-05 | 2012-01-11 | 周亚伟 | Effective components of peony leaves as well as preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273961A (en) * | 2000-01-28 | 2000-11-22 | 中国科学院广州化学研究所 | Process for extracting peonol with supercritical or liquid-state CO2 |
| CN1187069C (en) * | 2002-11-26 | 2005-02-02 | 安徽省天尊医药科技研究所 | Method for extracting coxtex mouten total glucoside for treating hepatitis |
-
2005
- 2005-12-14 CN CN2005101223493A patent/CN1981819B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273961A (en) * | 2000-01-28 | 2000-11-22 | 中国科学院广州化学研究所 | Process for extracting peonol with supercritical or liquid-state CO2 |
| CN1187069C (en) * | 2002-11-26 | 2005-02-02 | 安徽省天尊医药科技研究所 | Method for extracting coxtex mouten total glucoside for treating hepatitis |
Non-Patent Citations (2)
| Title |
|---|
| 吴少华等.丹皮的化学成分研究.《中草药》.2002,第33卷(第8期),679-680. * |
| 周红涛等.赤芍与白芍的化学成分含量比较研究.《中国药学杂志》.2003,第38卷(第9期),654-657. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1981819A (en) | 2007-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101642450A (en) | New application of dicaffeoylquinic acid | |
| CN102362971B (en) | A kind of preparation method and preparation for the treatment of coronary heart disease Chinese medicine and effective chemical constituent thereof | |
| Niu et al. | Study on antibacterial effect of medlar and hawthorn compound extract in vitro | |
| CN102516213B (en) | Sesquiterpene compound and preparation method and application thereof | |
| CN1981819B (en) | Tree-peony root bark component, its preparation, making method and use | |
| CN1989984B (en) | Chuanxiong rhizome effective ingredient, preparing method, preparation and use thereof | |
| CN1981822B (en) | Tree-peony root bark effective component, its preparation, making method and use | |
| CN1989985B (en) | Chuanxiong rhizome effective ingredient, preparing method, preparation and use thereof | |
| Rahhal et al. | Phytochemical investigation and diuretic activity of the Palestinian rataegus aronia in mice using an aqueous extract | |
| CN1981809B (en) | Danshen effective component, its preparation, making method and usage | |
| CN100340255C (en) | Moutan bark effective constituent and preparation method thereof | |
| CN1981820A (en) | Tree-peony root bark effective component, its preparation, making method and use | |
| CN1981821A (en) | Tree-peony root bark effective component, its preparation, making method and use | |
| CN1989986B (en) | Chuanxiong rhizome effective ingredient, preparing, preparation method and use thereof | |
| CN106109862A (en) | A kind of Rhizoma Paridis extract treating viral influenza | |
| CN1981810B (en) | Danshen component, preparation, making method and usage | |
| CN105796637A (en) | Anti-breast cancer traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN1981811B (en) | Danshen effective component, its preparation, making method and usage | |
| CN100427115C (en) | Effective part and preparation method of traditional Chinese medicine paeonol for treating cardiovascular disease | |
| CN102125590B (en) | Ginsenoside Rg1-containing pseudo-ginseng active ingredient as well as preparation method and application thereof | |
| CN1981790B (en) | Rhizoma Chuanxiong effective components and production thereof | |
| CN102240328A (en) | Traditional Chinese medicine for treating cold and preparation method thereof | |
| CN108743654B (en) | A kind of traditional Chinese medicine composition for treating ischemic heart disease and its preparation method and application | |
| Liang et al. | Study on the small intestine absorptive kinetics characters of tanshinol and protocatechualdehyde of Salvia miltiorrhiza extracts in rats in vivo. | |
| CN101474264A (en) | Effective component of white peony root as well as preparation method and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070511 Address after: Hedong District of Beichen Puji road in Tianjin No. 2 city of the modern Chinese Medicine Applicant after: Tianjin Tianshili Pharmaceutical Co., Ltd. Address before: White road, Beichen science and Technology Park in Tianjin City Xinyi Liaohe Road No. 1 Applicant before: Tianshili Modern Traditional Chinese Medicine Research & Devleopment Co., Ltd., |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110720 Termination date: 20191214 |